

Macular Degeneration Guideline Committee – development

Date: 5th and 6th September 2016

Location: NICE offices, Manchester

Minutes: Final

Committee members present:		
	Day 1	Day 2
Nick Beare (NB) Acting Chair	Present for all items	Present for all items
Katy Barnard (KB)	Apologies	Present for all items
Cathie Burke (CB)	Present for all items	Present for all items
Jennifer Evans (JE)	Apologies	Present until partway through item 5
Mary Freeman (MF)	Apologies	Present for all items
Alexander Foss (AF)	Apologies	Present for all items
Carol McCletchie (CM)	Present for all items	Present for all items
Elizabeth Wick (EW)	Present for all items	Present for all items
Cathy Yelf (CY)	Present for all items	Present until partway through item 5

In attendance:		
	Day 1	Day 2
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present from partway through item 2	Apologies
Sue Ellerby (SE)	Present for all	Present for all

Macular Degeneration Guideline Committee 9 minutes

ICG – Clinical Advisor	items	items
Chris Gibbons (CG) ICG – Technical Analyst (HE)	Present for all items	Present for all items
Kate Moring (KM) NICE – Business Analyst	Apologies	Present for all items
Vonda Murray (VM) ICG – Project Manager	Present for all items	Present for all items
Gabriel Rogers (GR) ICG – Technical Advisor (HE)	Present for all items	Present for all items
Yingying Wang (YW) ICG – Technical Analyst	Present for all items	Present for all items

Observers:	Day 1	Day 2
Helen Dickenson NICE – Commissioning Coordinator	Present for all items	Present for all items
Judith Hughes PhD student	Present from item 6	Present for all items

Attendees sending apologies for both Day 1 and Day 2:	
Andy Charley	Committee member
Caroline Keir	NICE – Guideline Commissioning Manager
Dave Nicholls	NICE – Information Specialist
Ellen Rule	Committee member
Waqaar Shah (WS)	Committee Chair
Mary-Ann Sherratt	Committee member
Sue Spiers	NICE – ICG, Associate Director

DAY 1

**Item 1.
Introductions, apologies, minutes, DOI and objectives for the meeting**

NB (Acting Chair) welcomed the Committee members, attendees and observers to day 1 of the 9th Guideline Committee meeting for age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

It was highlighted that the committee were not quorate, and therefore it was agreed that no recommendations would be made before the evidence was reviewed at a quorate committee meeting.

The Acting Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
Nick Beare	Ophthalmology supervisor to an Ophthalmology trainee who has received an award from Bayer to study Post-Ebola uveitis in Sierra Leone. The award is from Bayer's Global Ophthalmology Award Programme and is paid to the University of Liverpool Institute of Translational Medicine.	Declare and participate

The above conflict was classified as a non-specific, non-personal financial conflict and it was agreed that NB was able to continue to Chair the meeting in the absence of the substantive committee Chair (WS). Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting.

The minutes were reviewed from GComm 8; 13th July 2016 and agreed as an accurate record of the meeting and approved.

**Item 2.
Chapter introductions**

This item was deferred due to the low number of attendees to the meeting

Item 3.

RQ12 - What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18 - What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

- Introduction
- Presentation of clinical evidence
- Agree evidence statements

The Committee agreed that this item would be deferred until day 2, when more members of the committee were expected to attend.

This item was replaced by item 4 from day 2's agenda

RQ7 - What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?

- Presentation of clinical evidence
- Agree evidence statements
- Draft recommendations

YW presented evidence on the effectiveness of interventions (statins, omega-3 fatty acid and laser treatment of drusen) on slowing AMD progression. The committee discussed the evidence but declined to make any recommendations due to the meeting not being quorate. It was agreed that a summary of presented evidence and discussion will be presented at the next committee meeting to enable further discussion and the drafting of any recommendations.

Item 4.

RQ12 - What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18 - What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

- Systematic review of published health economic evaluations
- Agree evidence statements

Item 5.

RQ12 - What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18 - What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

- Health economics new
- Agree evidence statements
- Draft recommendations

The Committee agreed item 4 and 5 would be deferred until day 2, when more members of the committee were expected to attend.

Item 6.

Any other business

None

Item 7.

Summary and next steps

The Acting Chair briefly summarised the discussions from the meeting before closing day 1.

DAY 2

Item 1.

Introductions, apologies, minutes, DOI and objectives for the meeting

The Acting Chair welcomed the Committee members, attendees and observers to day 2 of the 9th Guideline Committee meeting on age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

The Acting Chair invited each attendee to declare any new conflicts. No new conflicts were declared.

Having reviewed all previous and current declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Item 2.

Resource impact

KM briefed the committee on the role of resource impact in guideline development.

Item 3.

RQ23 - What strategies and tools are useful for monitoring and self-monitoring for people with AMD? -Strategies and tools for monitoring

- Presentation of clinical evidence
- Agree evidence statements
- Draft recommendations

The Committee agreed to defer this Item until a later meeting, because of changes to day 1's agenda. The item was replaced by item 3 from day 1.

RQ12 - What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18 - What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

- Introduction Presentation of clinical evidence
- Pairwise data (inc. meta-analysis)
- Network meta-analysis

GR provided an overview of how the evidence will be presented for review questions 12 and 18.

YW presented the clinical evidence on the effectiveness of different anti-angiogenic therapies for the treatment of neovascular AMD, and the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD.

GR provided an introduction to pairwise and network meta-analysis. GR presented the results of the network meta-analysis for the effectiveness of different anti-angiogenic therapies for the treatment of neovascular AMD.

GR presented the proposed health economics model for the guideline.

Item 4.

RQ7 - What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?

- Presentation of clinical evidence
- Agree evidence statements
- Draft recommendations

This item had been presented and discussed on day 1, and was replaced by item 4 from day 1

RQ12 & RQ18

- Systematic review of published health economic evaluations
- Agree evidence statements

Due to time constraints the committee agreed to defer this item until a future meeting.

Item 5.

Recap

Due to time constraints the committee agreed to defer this item until a future meeting. The item was replaced by item 5 from day 1.

RQ12 - What is the effectiveness of different anti-angiogenic therapies (including photodynamic therapy) for the treatment of neovascular AMD?

RQ18 - What is the effectiveness of different frequencies of administration for anti-VEGF regimens for the treatment of neovascular AMD?

- Health economics new
- Agree evidence statements
- Draft recommendations

Due to time constraints the committee agreed to defer this item until a future meeting.

Item 6.

Any other business

None

Item 7.

Summary and next steps

The Acting Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

Date of next meeting:	GDG 10 - Monday 24th October 2016
Location of next meeting:	NICE offices, London

Full list of remaining dates:

GComm10 - Monday 24th October 2016	London
GComm11 - Tuesday 6th and Wednesday 7th December 2016	Manchester
Gcomm 12 - Thursday 5th January 2017	Manchester
Post Consultation Meeting - Monday 24th April 2017	Manchester